Adeno-associated virus (AAV) as a delivery vehicle. Production delays.

A recent article noted that recombinant AAV production facilities worldwide were currently committed to covid-19 vaccine production and that this might delay any proposed clinical trials to treat patients with Rett Syndrome. This short article provides some background on AAV and the difficulties in scaling up production to permit an…

Discussion Group – What Else Affects Communication

A talk by Tracey Campbell, Abigail Davison-Hoult and Gill Townend 18 June 2021, 5:00 am AEST REGISTRATION IS FREE - Book Your Place Here About this talk Join us for the fifth Discussion Group of 2021. In this session we will be focussing on Kate Ahern and Judy Lariviere's talks on the impact…

Staying Resilient (self) Discussion Group

Start date & time  29 June, 2021 - 10:00 End date & time  29 June, 2021 - 11:00 Venue  Online Status  View event details for more information. Rett UK are pleased to offer to all families a series of webinars from Gooding & Wood to help Rett families navigate through…

9th World Rett Syndrome Congress – Further Postponement

The COVID-19 pandemic causes YET another postponement of the 9th World Rett Syndrome Congress What with the influence that the COVID-19 pandemic is still having around the world, the uncertainty of both travel restrictions and extent of the vaccination process, the Committee of the Rett Syndrome Association of Australia (RSAA) has decided…

Running 4 Andee – Gold Coast Marathon

Andee's father wrote "In July 2019 my then 8 year old daughter was diagnosed with Rett Syndrome."   Rett Syndrome is a rare neurological disorder that affects a person's ability to walk, talk, or purposely use their hands.   Rett Syndrome is like having Cerebral Palsy, Epilepsy, Autism, Parkinson's, anxiety, and breathing…

Novartis and gene therapy to treat Rett Syndrome.

Novartis, a multinational biotechnology company, issued a statement in August 2020 to confirm full commitment to their gene therapy program for Rett Syndrome. This was followed by a press release from the company in March 2021 which reported recent results of gene therapy to treat patients with spinal muscular atrophy…

Annual Report

The draft Annual Report for 2019-2020 is now available for viewing and downloading.   The report will be presented at the Annual General Meeting on 31st October 2020. To open the report please click the link below.   RSAA annual report 2019-2020 semi final

Annual General Meeting

Dear RSAA Members Our AGM will be held on Saturday 31st October 2020 at: 4.00 pm (AEDT), 3.30 pm (SA Time), 3.00 pm (OLD Time) 1.00 pm (WA Time).   As COVID 19 prevents us from meeting in person, the AGM will be held online. You are invited to join the meeting and we would…
Share this story